Transforming the way we treat and cure viral infections today
Evrys Bio is developing safe and effective, first-in-class therapies that can simultaneously treat a broad spectrum of viruses, while preventing drug resistance.
Novel, First-in-Class Approach
Allosteric, small molecule SIRT2 modulators targeting host cells to suppress viral infections and prevent drug-resistance
Broad Spectrum Applicability
SIRT2 modulation shifts metabolic reprogramming that can target a broad spectrum of pathogens and address conditions beyond infectious disease
Strategic Drug Development Plan
EV-100 is a clinic-ready asset poised to rapidly generate proof-of-concept data and derisk SIRT2-centered platform
Led By Team of Experts
Founded by established drug development leaders, backed by renowned scientific advisors and significant non-dilutive funding